Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: An ancillary analysis from the BOREALIS trial — Ying Bai (2020) | RDL Network
Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: An ancillary analysis from the BOREALIS trial
In the BOREALIS trial, the risk of adjudicated stroke/SE, major bleedings, and all-cause death was not related to mild-moderate follow-up changes in kidney function (±30 mL/min). The risk of all-cause death was significantly increased in AF patients with abruptly deteriorating kidney function.
Giuseppe Boriani, Cécile Laroche, Igor Diemberger, Mircea Ioachim Popescu, Lars Hvilsted Rasmussen, Lucian Petrescu, Harry J.G.M. Crijns, Luigi Tavazzi, Aldo Maggioni, Professor Gregory Lip
Yang Liu, Steven Ho Man Lam, Giulio Francesco Romiti, Bi Huang, Yang Chen, Tze-Fan Chao, Brian Olshansky, Kui Hong, Menno V. Huisman, Professor Gregory Lip
Giuseppe Boriani, Marco Proietti, C Laroche, Igor Diemberger, Zbigniew Kalarus, Tatjana Potpara, Laurent Fauchier, Harry J.G.M. Crijns, Aldo P. Maggioni, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.